Patents by Inventor Andrew T. Watt

Andrew T. Watt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20140194492
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Methods for treating hypercholesterolemia
    Patent number: 8664190
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: March 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20120077865
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: November 22, 2011
    Publication date: March 29, 2012
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. FREIER, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Methods for treating hypercholesterolemia
    Patent number: 8093222
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: January 10, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Methods for treating hypercholesterolemia
    Patent number: 8084437
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: December 27, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
    Publication number: 20110098340
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with expression of BCL2-associated X protein are provided.
    Type: Application
    Filed: December 2, 2010
    Publication date: April 28, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Hong Zhang, Andrew T. Watt
  • Antisense modulation of BCL2-associated X protein expression
    Patent number: 7846730
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with expression of BCL2-associated X protein are provided.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: December 7, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Hong Zhang, Andrew T. Watt
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20100144834
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: November 27, 2007
    Publication date: June 10, 2010
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina Lemonidis Tarbet, Sanjay Bhanot, Diane Tribble, Andrew T. Watts
  • Antisense modulation of connective tissue growth factor expression
    Patent number: 7709630
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: May 4, 2010
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: William Gaarde, Andrew T Watt, Brett P Monia, Mausumee Guha
  • Modulation of the RNA interference pathway
    Patent number: 7709453
    Abstract: Compounds, compositions and methods are provided for modulating the RNAi pathway. The compositions comprise oligonucleotides, targeted to nucleic acid molecules encoding EIF2C2. Methods of using these compounds for modulation of RNA interference as well as EIF2C2 expression and for diagnosis and treatment of disease associated with expression of EIF2C2 are provided. Also provided are compounds, compositions and methods for modulating the expression of DDX36. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DDX36. Methods of using these compounds for modulation of DDX36 expression and for diagnosis and treatment of diseases and conditions associated with expression of DDX36 are provided.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 4, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
    Publication number: 20100035964
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Application
    Filed: January 28, 2008
    Publication date: February 11, 2010
    Inventors: William Gaarde, Andrew T. Watt, Brett P. Monia, Mausumee Guha
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20090318536
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: June 4, 2009
    Publication date: December 24, 2009
    Applicant: ISS PHARMACEUTICALS, INC.
    Inventors: Susan M. FREIER, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Antisense modulation of helicase-moi expression
    Patent number: 7427470
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: September 23, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of connective tissue growth factor expression
    Patent number: 6965025
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: November 15, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: William Gaarde, Andrew T. Watt
  • Antisense modulation of interferon gamma receptor 2 expression
    Patent number: 6870046
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 2. Methods of using these compounds for modulation of Interferon gamma receptor 2 expression and for treatment of diseases associated with expression of Interferon gamma receptor 2 are provided.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: March 22, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of dual specific phosphatase 5 expression
    Patent number: 6867039
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 5. Methods of using these compounds for modulation of dual specific phosphatase 5 expression and for treatment of diseases associated with expression of dual specific phosphatase 5 are provided.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: March 15, 2005
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Andrew T. Watt
  • Antisense modulation of interferon gamma receptor 1 expression
    Publication number: 20040254133
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 1. Methods of using these compounds for modulation of Interferon gamma receptor 1 expression and for treatment of diseases associated with expression of Interferon gamma receptor 1 are provided.
    Type: Application
    Filed: April 28, 2004
    Publication date: December 16, 2004
    Inventors: C Frank Bennett, Andrew T Watt
  • Antisense modulation of FLIP-c expression
    Publication number: 20040254137
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of FLIP-c. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FLIP-c. Methods of using these compounds for modulation of FLIP-c expression and for treatment of diseases associated with expression of FLIP-c are provided.
    Type: Application
    Filed: October 27, 2003
    Publication date: December 16, 2004
    Inventors: Elizabeth J. Ackermann, C. Frank Bennett, Hong Zhang, Andrew T. Watt, William Ricketts, Nicholas M. Dean
  • Antisense modulation of phospholipase a2, group vi (ca2+independent) expression
    Publication number: 20040248297
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group VI (Ca2+-independent). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group IV (Ca2+-independent). Methods of using these compounds for modulation of Phospholipase A2, group VI (Ca2+-independent) expression and for treatment of diseases associated with expression of Phospholipase A2, group VI (Ca2+-independent) are provided.
    Type: Application
    Filed: November 5, 2003
    Publication date: December 9, 2004
    Inventors: C. Frank Bennett, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of PLML expression
    Patent number: 6825337
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PLML. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PLML. Methods of using these compounds for modulation of PLML expression and for treatment of diseases associated with expression of PLML are provided.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: November 30, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt